Clinical Research Directory
Browse clinical research sites, groups, and studies.
7 clinical studies listed.
Filters:
Tundra lists 7 Thyroid Eye Disease (TED) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06812325
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-04-08
11 states
NCT07257185
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-03-30
1 state
NCT07262476
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-03-30
1 state
NCT07404111
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
The goal of this study is to evaluate the safety, tolerability, and efficacy of KRIYA-586 (VV-14305) in treating thyroid eye disease (TED).
Gender: All
Ages: 18 Years - 80 Years
Updated: 2026-02-11
1 state
NCT06569758
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-02-11
1 state
NCT07308964
Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease
The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED). The main question it aims to answer is: \* Is a shorter course equally effective and safe for patients who respond well early in treatment. Participants who demonstrate an early clinical response as part of their treatment with Teprotumumab will receive a shorter protocol of 4 infusions instead of the standard 8.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-30
NCT07211776
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Gender: All
Ages: 18 Years - 75 Years
Updated: 2025-12-29